Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis

Clicks: 184
ID: 273101
2020
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
We used data from a trial of patients with UC to develop a scoring system, called the CDST, which identified patients most likely to enter corticosteroid-free remission during vedolizumab therapy, but not anti-TNF therapy. We validated the vedolizumab CDST in a separate cohort of patients in clinica …
Reference Key
ps2020clinicaldevelopment Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Dulai PS;Singh S;Casteele NV;Meserve J;Winters A;Chablaney S;Aniwan S;Shashi P;Kochhar G;Weiss A;Koliani-Pace JL;Gao Y;Boland BS;Chang JT;Faleck D;Hirten R;Ungaro R;Lukin D;Sultan K;Hudesman D;Chang S;Bohm M;Varma S;Fischer M;Shmidt E;Swaminath A;Gupta N;Rosario M;Jairath V;Guizzetti L;Feagan BG;Siegel CA;Shen B;Kane S;Loftus EV;Sandborn WJ;Sands BE;Colombel JF;Lasch K;Cao C;;
Journal clinical gastroenterology and hepatology : the official clinical practice journal of the american gastroenterological association
Year 2020
DOI
DOI not found
URL
https://www.pubmed.gov/32062041/
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine treatment outcome research support non-u.s. gov't Remission Induction Antibodies Monoclonal Colitis humanized / therapeutic use ulcerative* / drug therapy pmid:32062041 pmc7899124 doi:10.1016/j.cgh.2020.02.010 parambir s dulai siddharth singh charlie cao gastrointestinal agents / therapeutic use

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.